Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye

Ávila, Marcel Y.; Igua, Angela M; Mora, Amparo M

doi:10.1136/bjophthalmol-2018-312072

Cited by 35 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro and clinical studies have investigated the applicability of PRP as a therapeutic agent in nerve injuries [24], myocardial infarction [25], cosmetic surgery [26,27] and eye disease [28]. Furthermore, PRP has been increasingly utilized in sports medicine to treat ligament and tendon lesions due to its association with shortened recovery times and improved functional outcomes, but there is a paucity of good-quality scientific evidence demonstrating its effectiveness [29,30].…”

Section: Introductionmentioning

confidence: 99%

The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study

Melo

Navarro²,

Jones

et al. 2020

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To investigate the impact of a 3-month course of intracortical injections of autologous platelet-rich plasma (PRP) upon ovarian reserve markers versus no intervention in women with low ovarian reserve prior to undergoing assisted reproductive technology (ART). Methods Prospective controlled, non-randomized comparative study conducted in a private fertility clinic, in Venezuela. Women with abnormal ovarian reserve markers (FSH, AMH and AFC) who declined oocyte donation were allocated to one of the following groups according to patient choice: monthly intracortical ovarian PRP injections for three cycles, or no intervention. Primary outcomes were the change in FSH, AMH and AFC pre-and post-treatment. Secondary outcomes included the number of oocytes collected and fertilized, biochemical/clinical pregnancy rates and miscarriage and live birth rates. Results Eighty-three women were included, of which 46 received PRP treatment and 37 underwent no intervention. Overall median age was 41 years (IQR 39-44). There were no demographic differences between the study groups. At the 3-month follow-up, women treated with PRP experienced a significant improvement in FSH, AMH and AFC, whereas there was no change in the control group. Furthermore, overall rates of biochemical (26.1% versus 5.4%, P = 0.02) and clinical pregnancy (23.9% versus 5.4%, P = 0.03) were higher in the PRP group, while there was no difference in the rates of first trimester miscarriage and live birth between groups. Conclusion PRP injections are effective and safe to improve markers of low ovarian reserve prior to ART, although further evidence is required to evaluate the impact of PRP on pregnancy outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study

Melo

Navarro²,

Jones

et al. 2020

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…It was suggested that PRP improved patients' symptoms significantly. It was also reported that the tear volume was increased after the injection of PRP [52]. Acceleration and improvement of tissue regeneration are caused by growth factors released from the platelets [67].…”

Section: Growth Factor Deliverymentioning

confidence: 95%

Bioengineering Approaches for Corneal Regenerative Medicine

Mahdavi

Abdekhodaie

Mashayekhan

et al. 2020

Tissue Eng Regen Med

View full text Add to dashboard Cite

BACKGROUND: Since the cornea is responsible for transmitting and focusing light into the eye, injury or pathology affecting any layer of the cornea can cause a detrimental effect on visual acuity. Aging is also a reason for corneal degeneration. Depending on the level of the injury, conservative therapies and donor tissue transplantation are the most common treatments for corneal diseases. Not only is there a lack of donor tissue and risk of infection/rejection, but the inherent ability of corneal cells and layers to regenerate has led to research in regenerative approaches and treatments. METHODS: In this review, we first discussed the anatomy of the cornea and the required properties for reconstructing layers of the cornea. Regenerative approaches are divided into two main categories; using direct cell/growth factor delivery or using scaffold-based cell delivery. It is expected delivered cells migrate and integrate into the host tissue and restore its structure and function to restore vision. Growth factor delivery also has shown promising results for corneal surface regeneration. Scaffold-based approaches are categorized based on the type of scaffold, since it has a significant impact on the efficiency of regeneration, into the hydrogel and non-hydrogel based scaffolds. Various types of cells, biomaterials, and techniques are well covered. RESULTS: The most important characteristics to be considered for biomaterials in corneal regeneration are suitable mechanical properties, biocompatibility, biodegradability, and transparency. Moreover, a curved shape structure and spatial arrangement of the fibrils have been shown to mimic the corneal extracellular matrix for cells and enhance cell differentiation. CONCLUSION: Tissue engineering and regenerative medicine approaches showed to have promising outcomes for corneal regeneration. However, besides proper mechanical and optical properties, other factors such as appropriate sterilization method, storage, shelf life and etc. should be taken into account in order to develop an engineered cornea for clinical trials.

show abstract

“…Among all studies treating dry eye diseases (DED), Avila et al 27 was designated at clinical evidence level II, and Garcia-Conca et al 28 at clinical level III. Both studies included a comparison group and used PRP eye drops.…”

Section: Primary and Secondary Dry Eye Diseasesmentioning

confidence: 99%

<p>Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review</p>

You¹,

Hodge²,

Hoque³

et al. 2020

OPTH

View full text Add to dashboard Cite

Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.

show abstract

Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye

Abstract: NCT02257957.

Cited by 35 publications

References 16 publications

The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study

The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study

Bioengineering Approaches for Corneal Regenerative Medicine

<p>Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review</p>

Contact Info

Product

Resources

About